-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, there have been reports that Merck is about to reach the acquisition of the pharmaceutical company Acceleron for US$11 billion
.
This amount may set a new record for Merck’s transaction volume since it acquired Schering-Plough for US$41.
1 billion
.
Public information shows that Acceleron is a clinical-stage biopharmaceutical company that focuses on the research and development of anti-cancer drugs and orphan drugs for rare diseases.
The current pipeline products are mainly for the respiratory system and hematology
.
The industry believes that this acquisition marks Merck's breakthrough layout in the field of rare diseases
.
It should be noted that in the field of rare diseases, due to the difficulty in research and development, the narrow audience, and the sky-high price brought by research and development costs, in the past, major pharmaceutical companies have avoided discussing research and development directions
.
However, in recent years, it is obvious that multinational leading pharmaceutical companies are stepping into this field one after another, and have set a history of various large-scale mergers and acquisitions
.
In addition to Merck’s upcoming US$11 billion acquisition of Acceleron, in fact, as early as April 2018, Takeda Pharmaceuticals acquired the rare disease giant Shire for US$65 billion; in December 2020, AstraZeneca also acquired US$39 billion.
Acquiring the rare disease giant company Alexion.
.
.
According to incomplete statistics, the cumulative amount of mergers and acquisitions in the rare disease field in the past five years has far exceeded 100 billion US dollars
.
In this regard, industry analysts believe that the reason why the rare disease market has attracted major pharmaceutical companies to vie for deployment is mainly because it has a lot of room for development to be explored
.
According to the "Orphan Drug Report 2019" released by the pharmaceutical market research agency evaluate Pharma, the global orphan drug market in 2018 was approximately US$131 billion, and this scale will grow at a compound annual growth rate of 12.
3%; by 2024, its market size will be Reached 242 billion US dollars, accounting for one-fifth of the global prescription drug market share
.
Of course, in addition to having a huge market prospect, the industry has proposed that there are multiple factors that are also attracting major pharmaceutical companies to increase their participation
.
For example, from the perspective of research and development, the probability of success of rare disease drugs from clinical to approval is also higher, which is shorter than other indications.
.
In addition, in terms of investment value, orphan drug is of great benefit to the valuation of listed companies, because once it is successfully listed, it will become the "king bomb" in the field of indications
.
At present, based on the above advantages, in addition to multinational pharmaceutical companies, domestic pharmaceutical companies are also increasing their exploration in the field of rare diseases
.
Especially under favorable policies, as many innovative pharmaceutical companies have joined the development of rare disease drugs, China's rare disease drug research and development has gradually begun to make breakthroughs
.
As of now, there are 24 Chinese new drugs that have obtained orphan drug qualifications in the United States in 2020
.
Among these products, mainly anti-tumor drugs, but also anti-infection and other rare disease drugs
.
In general, R&D investment in the field of rare drugs will not only bring patent income and monopoly market share to pharmaceutical companies, but also bring certain social prestige to the company
.
Therefore, in view of the current domestic policies that continue to promote pharmaceutical companies to enter the field of rare diseases, more and more pharmaceutical companies will accelerate the deployment of rare disease drugs in the future, and this is expected to benefit more patients and make them incurable.
The situation has been further improved, and help more families to reduce the burden
.
.
This amount may set a new record for Merck’s transaction volume since it acquired Schering-Plough for US$41.
1 billion
.
Public information shows that Acceleron is a clinical-stage biopharmaceutical company that focuses on the research and development of anti-cancer drugs and orphan drugs for rare diseases.
The current pipeline products are mainly for the respiratory system and hematology
.
The industry believes that this acquisition marks Merck's breakthrough layout in the field of rare diseases
.
It should be noted that in the field of rare diseases, due to the difficulty in research and development, the narrow audience, and the sky-high price brought by research and development costs, in the past, major pharmaceutical companies have avoided discussing research and development directions
.
However, in recent years, it is obvious that multinational leading pharmaceutical companies are stepping into this field one after another, and have set a history of various large-scale mergers and acquisitions
.
In addition to Merck’s upcoming US$11 billion acquisition of Acceleron, in fact, as early as April 2018, Takeda Pharmaceuticals acquired the rare disease giant Shire for US$65 billion; in December 2020, AstraZeneca also acquired US$39 billion.
Acquiring the rare disease giant company Alexion.
.
.
According to incomplete statistics, the cumulative amount of mergers and acquisitions in the rare disease field in the past five years has far exceeded 100 billion US dollars
.
In this regard, industry analysts believe that the reason why the rare disease market has attracted major pharmaceutical companies to vie for deployment is mainly because it has a lot of room for development to be explored
.
According to the "Orphan Drug Report 2019" released by the pharmaceutical market research agency evaluate Pharma, the global orphan drug market in 2018 was approximately US$131 billion, and this scale will grow at a compound annual growth rate of 12.
3%; by 2024, its market size will be Reached 242 billion US dollars, accounting for one-fifth of the global prescription drug market share
.
Of course, in addition to having a huge market prospect, the industry has proposed that there are multiple factors that are also attracting major pharmaceutical companies to increase their participation
.
For example, from the perspective of research and development, the probability of success of rare disease drugs from clinical to approval is also higher, which is shorter than other indications.
.
In addition, in terms of investment value, orphan drug is of great benefit to the valuation of listed companies, because once it is successfully listed, it will become the "king bomb" in the field of indications
.
At present, based on the above advantages, in addition to multinational pharmaceutical companies, domestic pharmaceutical companies are also increasing their exploration in the field of rare diseases
.
Especially under favorable policies, as many innovative pharmaceutical companies have joined the development of rare disease drugs, China's rare disease drug research and development has gradually begun to make breakthroughs
.
As of now, there are 24 Chinese new drugs that have obtained orphan drug qualifications in the United States in 2020
.
Among these products, mainly anti-tumor drugs, but also anti-infection and other rare disease drugs
.
In general, R&D investment in the field of rare drugs will not only bring patent income and monopoly market share to pharmaceutical companies, but also bring certain social prestige to the company
.
Therefore, in view of the current domestic policies that continue to promote pharmaceutical companies to enter the field of rare diseases, more and more pharmaceutical companies will accelerate the deployment of rare disease drugs in the future, and this is expected to benefit more patients and make them incurable.
The situation has been further improved, and help more families to reduce the burden
.
